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Abstract
Phenylethanolamine N-methyltransferase (PNMT) catalyzes the conversion of norepinephrine
(noradrenaline) to epinephrine (adrenaline) while, concomitantly, S-adenosyl-L-methionine
(AdoMet) is converted to S-adenosyl-L-homocysteine. This reaction represents the terminal step
in catecholamine biosynthesis and inhibitors of PNMT have been investigated, inter alia, as
potential antihypertensive agents. At various times the kinetic mechanism of PNMT has been
reported to operate by a random mechanism, an ordered mechanism in which norepinephrine
binds first, and an ordered mechanism in which AdoMet binds first. Here we report the results of
initial velocity studies on human PNMT in the absence and presence of product and dead end
inhibitors. These, coupled with isothermal titration calorimetry and fluorescence binding
experiments, clearly shown that hPNMT operates by an ordered sequential mechanism in which
AdoMet binds first. Although the logV pH-profile was not well defined, plots of logV/K versus pH
for AdoMet and phenylethanolamine, as well as the pKi versus pH for the inhibitor, SK&F 29661,
were all bell-shaped indicating that a protonated and an unprotonated group are required for
catalysis.
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INTRODUCTION
Phenylethanolamine N-methyltransferase (PNMT; E.C. 2.1.1.28) catalyzes the terminal step
in catecholamine biosynthesis, i.e., the conversion of norepinephrine (NE) to epinephrine
(Epi) with the concomitant conversion of S-adenosyl-L-methionine (AdoMet) to S-
adenosyl-L-homocysteine (AdoHcy) [1, 2] (Scheme 1). In addition to the high levels present
in the adrenal medulla, Epi makes up 5–10% of the total catecholamine content of the brain.
However, its function within the central nervous system (CNS) is not well understood [3].
CNS Epi has been implicated in a variety of activities including central control of blood
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pressure and respiration [4, 5], secretion of hormones from the pituitary [6], activation of the
K1-adrenoceptor [7] and may even be responsible for some of the neurodegeneration found
in Alzheimer’s disease [8, 9]. In light of this multitude of apparent activities considerable
effort has been expended in obtaining inhibitors of PNMT that could be used to delineate the
role of central Epi and even may be of pharmaceutical benefit [10–17].
The majority of the initial studies on PNMT inhibitors used partially purified homogenates
of adrenal glands from a variety of sources including monkey [2], rabbit [18, 19], rat [20],
bovine [21] and human [22]. It took more than thirty years for human PNMT (hPNMT) to
be cloned, expressed in E. coli and purified to homogeneity [23]. The purified enzyme was
used to show that structure-activity models derived from inhibition of the bovine enzyme
were likely to hold true for the human isozyme (hPNMT) [24, 25]. The availability of large
quantities of purified enzyme also enabled the crystallization of hPNMT [26] and, over the
past several years, X-ray structures have been obtained of hPNMT in complex with a
number of substrates and inhibitors [27–32]. In each case the complex also contained either
AdoMet or AdoHcy. The hPNMT complexes comprised the core class I AdoMet-dependent
methyltransferase fold [33, 34], along with a cap containing around 40% of the residues, that
interacts with the substrates/inhibitors and which completely covers the active site [27]
(Figure 1A). At present it is not clear how substrates/inhibitors access the active site but it
appears that a conformational change will be required. This may occur through movement of
cap to completely expose the active site, or movement of a flexible loop that blocks one end
of the site [27]. Further evidence suggestive of conformational changes is provided by
studies showing synergism in both substrate and inhibitor binding [30].
Over the years there were several studies aimed at understanding the kinetic mechanism of
PNMT. It was established rapidly that the reaction was irreversible, and was subject to
product inhibition by both Epi [35] and AdoHcy [36]. Connett and Kirshner [21] suggested
that, for bovine PNMT, both substrates could bind randomly, but that AdoMet was
kinetically preferred. Conversely, Pohorecky and Baliga proposed that the rat enzyme
operated by an ordered mechanism with norepinephrine binding first [20]. Pendleton and
Snow [18] used inhibition studies to propose that the mechanism for rabbit PNMT was also
ordered, but that AdoMet was the first substrate to bind. The latter observation was
confirmed for several rabbit PNMT isozymes, but it was also noted that some abortive
complexes were formed which could give rise to kinetic differences between isozymes [19,
37]. These proposed mechanisms were almost solely based on kinetic studies. In light of the
variability of the conclusions, and the apparent differences between species, here we have
used a combination of kinetic analysis, inhibition studies, isothermal titration calorimetry
and fluorescence spectrophotometry to investigate the kinetic mechanism of human PNMT.
In recent times, the mechanism of the reaction catalyzed by PNMT has also been studied
using computational approaches [38, 39]. The results showed that reaction took place via an
SN2 mechanism with methyl transfer being rate-limiting. The X-ray structure of the
hPNMT:AdoHcy:NE complex [32] shows that two glutamic acid residues, Glu185 and
Glu219, interact with the amine of NE, while an aspartic acid residue interacts with the
hydroxyl group of the side-chain. It is thought that both glutamates will take part in
catalysis, but the computational studies differ in their proposed roles for the two residues. In
an attempt to clarify the issue we have determined the pH-rate profile for the overall reaction
as well as the pH-profile for the binding of the inhibitor, SK&F 29661.
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MATERIALS and METHODS
Materials
The wild-type hPNMT expression plasmid, pET17PNMT-his, was available from an earlier
study [40]. Phenylethanolamine.HCl, octopamine.HCl, epinephrine.HCl, S-adenosyl-L-
methionine and S-adenosyl-L-homocysteine were obtained through Sigma. [3H]-S-
Adenosyl-L-methionine (15 Ci/mmol) was from Moravek Biochemicals or Amersham
Biosciences. SK&F 29661, SK&F 64139, LY134046, 3-trifluoromethyl phenylethanolamine
(3-CF3 PEA) and 7-nitro-1,2,3,4-tetrahydroisoquinoline (7-NO2 THIQ) were available from
a previous study as their hydrochloride salts [30]. All other buffers and reagents were the
highest grade commercially available.
Assays of hPNMT Activity
Cell growth, expression and purification of hPNMT were performed as described previously
[30]. The hPNMT-catalyzed reaction was followed by monitoring the transfer of a tritiated
methyl group from [3H]-AdoMet to phenylethanolamine (PEA) at 30 °C. A standard assay
mixture contained potassium phosphate (50 mM, pH 8.0), PEA (200 M) and AdoMet
including [3H]-AdoMet (5 μM), in a total volume of 250 μL. For determination of kinetic
constants, both substrate concentrations were varied between 0.3–3×Km. Following the
addition of enzyme, the reactions were incubated at 30 °C for 30 minutes, and then
quenched by the addition of 0.5 M boric acid (500 μL, pH 10.0). Two milliliters of a mixture
of toluene/isoamyl alcohol (7:3) were added, and the samples were vortexed for 30 seconds.
The phases were separated by centrifugation and an aliquot of the organic phase (1 mL) was
removed and added to 5 mL of scintillation fluid (Cytoscint, ICN). The radioactivity was
quantitated by liquid scintillation spectrometry.
Initial velocity data were fitted to eq 1 for a sequential mechanism using SigmaPlot 9.0
(SPSS Inc.).
(1)
Here, in Cleland’s nomenclature [41], [A] and [B] are substrate concentrations, KiA is the
dissociation constant for A, and Ka and Kb are the Michaelis constants (Km values) for A and
B, respectively.
Determination of inhibition constants (Ki values)
To obtain inhibition patterns the concentration of one substrate was fixed at its Km value (5
μM and 100 μM for AdoMet and PEA, respectively). The concentration of the second
substrate was then varied between 0.4–2.5×Km at several fixed inhibitor concentrations
(between 0–2.5×Ki). Depending on whether the inhibition patterns indicated competitive,
non-competitive or uncompetitive inhibition the initial velocity data were then fitted to eqs
2–4 using SigmaPlot.
(2)
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(3)
(4)
In eqs 2–4, [S] is the concentration of the varied substrate, [I] is the inhibitor concentration
and Kis and Kii are the slope and intercept inhibition constants, respectively.
Isothermal Titration Calorimetry
A VP-ITC instrument from MicroCal, LLC (GE Healthcare) was used to measure the
thermodynamic parameters of hPNMT binding to its substrates and/or inhibitors. The
hPNMT was stored in a buffer containing 20 mM Tris (pH 7.2), 1 mM EDTA, 0.5 mM
DTT, and 15% glycerol. Protein concentrations were determined using the Bradford method
[42]. The protein solution was diluted in 50 mM potassium phosphate (pH 8.0) to the
required concentration (25–200 μM) before being degassed and placed in the stirred
calorimetric cell. In some cases AdoMet or AdoHcy was added to the protein solutions prior
to degassing. Stock solutions of substrates and inhibitors were prepared by dissolving in
water and the solution pH was adjusted to 8.0. The titration solutions were prepared by
dilution of these stocks into 50 mM potassium phosphate (pH 8.0). An appropriate amount
of enzyme storage buffer was added to match the buffer concentration in the stirred cell.
After degassing the titration solution was placed in a 300 μL syringe. Generally, an initial
injection of 10 μL was followed by 25–29 injections of 9.5 μL at 180 sec intervals. Controls
for the heats of dilution and mixing were determined in separate experiments by titrations
carried out in the absence of enzyme. These titrations were subtracted from the experimental
analysis before the data were analyzed. The binding constants (KA) were obtained by fitting
data to a single-site model [43] using the Origin version 7.0 software supplied with the
MicroCal instrument.
Fluorescence spectrophotometry
Fluorescence measurements were carried out in potassium phosphate buffer (50 mM, pH
8.0) at room temperature on a Fluoromax-2 (Jobin Yvon) fluorescence spectrophotometer.
For all experiments, the excitation wavelength was 280 nm, and the emission spectra were
recorded from 310 to 400 nm. The quartz fluorescence cuvettes used for the measurement of
sample and blank spectra had a volume of 1 mL and a 10 mm path length. The enzyme
concentration of the samples was 10 μg/mL. Stock solutions for compounds used in the
fluorescence studies, AdoMet, AdoHcy, SK&F29661, SK&F64139, LY134046 were
prepared as described above. Aliquots of the stock solution were added from low to high
concentration to both the blank and sample, and the data were all corrected for dilution.
Fluorescence data were fitted to the equation for a rectangular hyperbola shown in eq 5,
(5)
where F is the change in intrinsic fluorescence upon addition of ligand to enzyme, Fmax is
the maximum change in fluorescence at infinite ligand concentration, [L] is ligand
concentration and Kd is the dissociation constant for the enzyme–ligand complex.
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pH Studies
The pH dependency of the hPNMT-catalyzed reaction of PEA and AdoMet was measured
over the range pH 6.0–10.0 at 30 °C in a buffer comprising ACES (100 mM) Tris (52 mM)
and ethanolamine (52 mM). Across this pH range the buffer provides a constant ionic
strength of 0.1 μM [44]. The reactions were carried out as described above and the kinetic
parameters, kcat,  and  were obtained by fitting initial rate data to eq 1. The
pH dependency of inhibition by SK&F 29661 was also measured and Ki values obtained by
fitting to eq 2. Data for the pH profiles were fitted to eq 6 or eq 7, as appropriate, using the
computer programs of Cleland [45].
(6)
(7)
In equations 6 and 7, y represents kcat, kcat/Km or 1/Ki, C is the pH independent value of y,
K1, K2 and K3 are acid dissociation constants, and H is the proton concentration.
RESULTS
Initial Velocity Studies
The structures of the various substrates and inhibitors are provided in Figure 2. The
hPNMT-catalyzed methylation of PEA has been shown previously to proceed in a linear
manner [46]. Initial velocity patterns were obtained by varying the concentration of one
substrate at different fixed concentrations of the other substrate. In each case the double-
reciprocal plots intersected to the left of the vertical axis (data not shown), consistent with
hPNMT operating by a sequential Bi Bi mechanism [47]. Data were fitted to eq 1 and the
kinetic parameters for PEA, octopamine and 3-CF3 PEA are summarized in Table 1.
The Km values for octopamine and 3-CF3-PEA were 20-fold and 200-lower, respectively,
than that of PEA. Further, even though PEA had the highest value of kcat, its kcat/Km value
was an order of magnitude lower than those of the other two substrates. Conversely, the Km
values for AdoMet were similar with all three substrates.
Product and Dead-end Inhibition Studies
Product inhibition patterns were obtained with both AdoHcy and Epi. AdoHcy was found to
be competitive against varied concentrations of AdoMet and non-competitive against PEA,
whereas Epi was found to be non-competitive against both PEA and AdoMet. 7-Nitro THIQ
was used as a dead-end analogue of PEA, and was found to be competitive against PEA as a
substrate and uncompetitive against AdoMet (Figure 3). The inhibition data, provided in
Table 2, are consistent with hPNMT operating by an ordered sequential mechanism with
AdoMet binding before PEA.
Isothermal Titration Calorimetry Studies
The interaction of hPNMT with several substrates and inhibitors was examined by ITC and
the data for binding of ligands to hPNMT are summarized in Table 3. A typical binding
curve is shown in Figure 4 and, for all the ligands examined, the data fit best to a single-site
model [43]. AdoMet and its product AdoHcy were found to bind to free hPNMT with
dissociation constants (Kd) of 4.6 and 2.9 μM, respectively. Conversely, substrates such as
PEA, NE, octopamine and 3-CF3 PEA did not bind to free hPNMT, binding only being
observed in the presence of AdoHcy. This provides further support for the suggestion that
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hPNMT operates by an ordered mechanism with AdoMet binding first. Epi was also found
bind to hPNMT in presence of either AdoMet or AdoHcy, although it did exhibit a 5-fold
preference for the latter. The dead-end inhibitors SK&F 29661 and SK&F 64139 were found
to bind to hPNMT in presence of AdoMet with Kd values similar to those obtained in initial
velocity studies. Intriguingly, the tight-binding inhibitors SK&F 64139 and LY 134046 were
also able to bind to free hPNMT (Table 3).
Fluorescence Studies
Fluorescence titrations were also employed to estimate the dissociation constants for
enzyme-reactant complexes. The ligands were all found to quench the fluorescence emission
of hPNMT, with a typical binding curve being shown in Figure 5. The Kd values obtained by
this method (Table 4), were found to be comparable to those obtained by ITC and/or kinetic
analysis.
pH Dependence of Kinetic Parameters
The pH dependence of the steady-state parameters was determined over the pH range of 6–
10. The pH dependence of the Ki value for SK&F 29661 was determined over the same
range. The pH-rate profiles are shown in Figure 6 and the data derived from them is shown
in Table 5. The logV profile is not simple, but appears to contain 3 pKas, each of which
causes partial inhibition when the group is protonated. The pKi profile and the logV/K
profiles are all bell shaped with slopes of unity on each side.
DISCUSSION
Methyltransferases show a diversity of kinetic mechanisms. For example, protoporphyrin
methyltransferase operates by a ping pong mechanism [48] whereas bacterial glutamyl
methyltransferase [49], DNA (cytosine) methyltransferase [50] and VP39, an mRNA cap-
specific O-methyltransferase [51] all operate via a random sequential mechanism. In
general, the small molecule methyltransferases such as guanidinoacetate N-
methyltransferase [52], histamine N-methyltransferase [53], acetylserotinin N-
methyltransferase [54] and glycine N-methyltransferase [55] have an ordered sequential
mechanism, in which AdoMet binds first. By contrast, PNMT has been variously described
as having mechanisms in which both substrates bound randomly [21], AdoMet bound first
[18], or NE bound first [20].
Overall, the data described herein suggest that hPNMT operates by an ordered sequential
mechanism at pH 8.0. An initial velocity pattern in which the lines intersect to the left of the
y-axis on a double reciprocal plot is indicative of a sequential mechanism. This was seen for
each of the three substrates examined (not shown). An ordered binding of substrates is
suggested by inhibition studies with both reaction products and dead-end inhibitors. AdoHcy
acts as a competitive inhibitor of AdoMet and as a non-competitive inhibitor of PEA,
whereas Epi acts non-competitively with both substrates. Taken together this implies that the
reaction is ordered and that AdoMet is the first substrate to bind [56]. This sequence is
confirmed by studies using the dead-end inhibitor, 7-NO2-THIQ. It was long thought that
THIQ inhibitors such as SK&F 29661 and SK&F 64139 occupied the NE binding site and
this was confirmed when the X-ray structures of the hPNMT:AdoHcy:octopamine [29] and
hPNMT:AdoHcy:NE [32] complexes were determined. Therefore it was not a surprise when
7-NO2-THIQ was found to be competitive with PEA. It was also found to be uncompetitive
with AdoMet, confirming that AdoMet bound prior to PEA (Figure 3). The fact that Epi
acted as a non-competitive inhibitor of PEA, the substrate it structurally mimics, indicates
that Epi can bind to two forms of the enzyme [56]. The first is the form to which PEA binds,
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i.e., the E:AdoMet complex. The second is likely to be the normal product complex,
E:AdoHcy.
The kinetic studies provide dissociation constants for the E:AdoMet complex (Kia) (Table 1)
and for the E:AdoHcy complex (Kii and Kis, Table 2), that are in the low micromolar range.
Almost identical results are obtained with both ITC (Table 3) and fluorescence
measurements (Table 4). In line with many small molecule methyltransferases [57], the Kd
values for AdoMet and AdoHcy are quite similar. It has been suggested that the in vivo
activity of many methyltransferases may be modulated by the intracellular [AdoMet] /
[AdoHcy] ratio [58–60] and it would seem that hPNMT is no exception.
The above kinetic results suggested that Epi could bind to both the E:AdoMet and
E:AdoHcy complexes. This prediction was confirmed by the ITC studies which showed Epi
binding with Kd values of 23 and 4 μM, respectively. Indeed, all substrates tested were
found to bind to the E:AdoHcy complex. That said, superposition of X-ray structures shows
that the NE binding sites are virtually identical, regardless of whether AdoMet or AdoHcy is
bound to the enzyme (not shown), so this may not be entirely unexpected. In fact, even when
occupied only by phosphate (as in PDB ID 3KPJ) the NE binding site does not change. It is
conceivable that, in addition to the [AdoMet] /[AdoHcy] ratio the intracellular [NE]/[Epi]
ratio may also play a role in modulating the action of hPNMT. In toto, based on the kinetic
and ligand binding studies, it would seem that the kinetic mechanism for hPNMT is the
ordered sequential mechanism shown in Figure 7.
As shown in Figure 1A, the binding sites for both substrates are enclosed by a tight cover
[27]. Moreover, to date, all X-ray structures of hPNMT have contained either AdoMet or
AdoHcy. This (i) would suggest that a conformational change will be required for substrates
to enter the hPNMT active site, and (ii) is consistent with an ordered mechanism with
AdoMet binding first. Prior to this study, hints of an ordered mechanism for hPNMT were
provided by a kinetic analysis which showed that the binding of inhibitors such as SK&F
29661 and 7-nitro THIQ was enhanced ~50-fold in the presence of AdoMet [30]. In the
present study, attempts to determine a Ki value for SK&F 29661 in the absence of AdoMet
or AdoHcy were unsuccessful. Conversely, the inhibitors with Ki values in the low
nanomolar range, SK&F 64139 and LY 134046 (Table 1), were able to bind to the enzyme
in the absence of AdoMet or AdoHcy. This was demonstrated by both ITC and fluorescence
experiments and, for both inhibitors, the Kd value obtained for binding to the free enzyme
was significantly (i.e., >100-fold) greater that that obtained for binding to hPNMT in the
presence of AdoMet. On that basis it would appear that (i) the two inhibitors are able to
access a binding site on the enzyme, (ii) the binding site is not optimal, and (iii) binding of
the co-substrate (or product) greatly improves the binding of the inhibitor. However, in the
absence of structural information, we cannot say whether the inhibitor occupies the same
binding site on the free enzyme as it does in the enzyme:substrate or enzyme:product
complex. Further, based on kinetic data [30], SK&F 29661 should bind to the free enzyme
with a Ki value around 6 μM but we saw no evidence of its binding, even at concentrations
up to the 25 μM used in these experiments. On the other hand, LY 134046 binds to the
hPNMT:AdoMet complex ~30 times more tightly than SK&F 29661 (Table 1).
Accordingly, based on the data in Tables 3 and 4 for the binding of LY 134046 to the free
enzyme, SK&F 29661 may be expected to bind to the free enzyme with a Ki value of ca. 130
μM. On that basis it is not surprising that we found no evidence of binding at 25 μM.
The NE binding site shows four ionizable residues that interact with NE (Figure 1B). Using
the structure of hPNMT in which NE has been replaced by phosphate (PDB ID 3KPJ), the
PROPKA program [61, 62] predicts that the sidechains of Lys57, Glu185, Glu219 and
Asp267 will have pKa values of 7.53, 7.33, 9.59 and 4.19, respectively. An earlier study
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showed that the kcat value of the K57A variant was unchanged, and the reduction in kcat
shown by the D267A variant was attributed to the inability of that variant to correctly
position the sidechain for catalysis [30]. Thus, and in accord with the computational studies,
it would seem that the pKas of two glutamate residues, 7.33 and 9.59, are likely to appear in
the pH-rate profiles.
The plot of logV versus pH (Figure 6A) is not simple. Although fitting to eq 7 provides 3
pKs (Table 5), it is also conceivable that the plot represents 2 pKs. The pK at ~9 causes
partial inhibition when the group is protonated and the second, at ~7, that causes further loss
of activity (W.W. Cleland, personal communication). Superficially, based on the PROPKA
results, the higher pKa could be attributed to Glu219, and the lower to Glu185.
The plot of logV/K for PEA is bell-shaped indicating that a protonated and an unprotonated
group are required for catalysis. Two pKas, of 8.66 and 9.26, were derived using eq 6. The
pKa of the side chain nitrogen of PEA is calculated to be 8.4 (Advanced Chemistry
Development Software; SciFinder). For a SN2 reaction to take place, this nitrogen needs to
be deprotonated so, potentially, is represented by the lower pKa in the logV/K profile. The
logV/K versus pH plot for AdoMet is also bell-shaped. Once again the higher pKa is similar
to that calculated for Glu219 but the second value, 7.25, is almost 1.5 pH units lower than
that seen in the PEA profile. Unlike the latter, AdoMet does not possess any ionizable
residues with pKa values in this range, so this lower value could be ascribed to Glu185.
The pKi versus pH plot for the THIQ inhibitor, SK&F 29661, suggests that both protonation
and deprotonation will reduce binding affinity, with pKas of 8.48 and 9.08 being derived
using eq 6. In addition, the pKa of the ring nitrogen of SK&F 29661 was determined to be
8.5 by pH titration (data not shown). As there is some evidence that THIQ inhibitors prefer
to bind in their neutral form [16], it is not unreasonable to attribute the observed pKa of 8.48
to the inhibitor as protonation of this group leads to a loss of activity. It is notable that in all
of the plots, a pKa of ~9 is observed. It is feasible that this belongs to the same group on the
enzyme, probably Glu219. However, one of the problems with interpreting this data is that
the observed pKa values are relatively close together. Cook and Cleland [56] caution that in
such cases the pH profile does not distinguish between which group must be protonated or
which group must be deprotonated for optimal activity.
In summary, these experiments have clearly demonstrated that hPNMT operates by an
ordered sequential mechanism, with AdoMet binding first. Further, it would appear that one
of the groups in the V/K profile is related to substrate binding as it does not appear in the V
profile. However, interpretation of the pH data is not so straightforward and, most likely,
will necessitate additional experiments in which the pKas of the ionizable groups are
perturbed through mutagenesis.
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hPNMT human phenylethanolamine N-methyltransferase
AdoMet S-adenosyl-L-methionine
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AdoHcy S-adenosyl-L-homocysteine
NE norepinephrine
Epi epinephrine
ITC isothermal titration calorimetry
PEA phenylethanolamine
THIQ tetrahydroisoquinoline
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Highlights
hPNMT operates by an ordered mechanism with AdoMet binding before
norepinephrine.
Epinephrine and AdoHcy both showed evidence of product inhibition.
THIQ inhibitors compete with phenylethanolamine but are uncompetitive with
AdoMet.
Binding of AdoMet increased the binding affinity of the second substrate/inhibitor.
logV/K pH profiles are all bell shaped with slopes of unity on each side.
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Figure 1.
(A) Structure of hPNMT in complex with AdoHcy (magenta) and SK&F 29661 (green). The
“cap” over the active site is in red. This figure was generated with PyMOL [64] using the
coordinates from the PDB entry, 1HNN. (B) Interaction of NE with ionizable residues in the
active site. Dotted lines indicate a distance of <3.5 Å. Figure based on PDB ID 3HCD.
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Figure 2.
Structures of hPNMT (A) substrates and (B) inhibitors used in this study.
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Figure 3.
Dead-end inhibition of hPNMT by 7-NO2-THIQ. The inhibition reactions were carried out
at 30 °C in 50 mM potassium phosphate buffer (pH 8.0). (A) The PEA concentration was
held at 100 μM. (B) The AdoMet concentration was 5 μM. In both cases the 7-NO2-THIQ
concentrations were 0 (●), 20 (○), 40 (▼), 80 (△), 120 (■) and 160 nM (□). The lines
represent fits of the data to eq 4 and 2, respectively.
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Figure 4.
Isothermal titration calorimetry (ITC) analysis of binding of AdoMet to hPNMT. The
reaction was carried at room temperature. The cell contained 25 μM hPNMT in 50 mM
KPO4 at pH 8.0 and the syringe contained 500 μM AdoMet in the same buffer. A total of 25
injections were made at 180 sec intervals. (Top panel) Raw ITC data. (Bottom panel) Data
for the integrated heat pulses, normalized per mol of injectant as a function of the molar
ratio ([AdoMet]/[hPNMT]). The binding curve (solid line) was best fit to a 1 site model
(inset).
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Figure 5.
Fluorescence binding curve for the interaction of AdoMet with hPNMT. Data recorded at
λex 280 nm and λem 348 nm were used in the analysis. The solid line represents the fit of the
data to eq 5 and provides a Kd of 3.3±0.2 μM. The double reciprocal plot (inset) provides a
Kd of 3.4±0.1 μM.
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Figure 6.
pH dependence of the kinetic parameters (A) kcat; (B) kcat/Km for AdoMet (●) and PEA (▼);
and (C) Ki for SK&F 29661. The data points are the experimentally determined values at 30
°C while the lines are theoretical based to fits of the data using eq 7 for A and eq 6 for B and
C.
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Figure 7.
Proposed kinetic mechanism for reaction of hPNMT with norepinephrine and S-adenosyl-
Lmethionine.
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Scheme 1.
Reaction catalyzed by hPNMT
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Table 3
Dissociation constants for ligand-hPNMT complexes from isothermal titration calorimetrya
Varied Ligand Fixed ligand Kd (varied ligand) (μM)
AdoMet – 4.6 ± 0.7
AdoHcy – 2.9 ± 0.9
Epi AdoHcy 4.1 ± 0.7
Epi AdoMet 23 ± 2.5
NE AdoHcy 7.2 ± 0.2
3-CF3-PEA AdoHcy 1.2 ± 0.3
PEA AdoHcy 60 ± 2
Octopamine AdoHcy 3.3 ± 0.1
SK&F 29661 AdoMet 0.19 ± 0.01
SK&F 29661 AdoHcy 7.4 ± 2.3
SK&F 29661 - n.d.b
SK&F 64139 – 0.42 ± 0.03
SK&F 64139 AdoMet 0.004 ± 0.001
LY 134046 – 3.2 ± 0.2
a
Binding studies were carried out at out as described in materials and methods. Data were fit to a one site model.
bNo evidence observed for inhibitor binding up to 25 μM
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Table 4
Dissociation constants for ligand-hPNMT complexes from fluorescence titrationa
Varied Ligand Fixed Ligand Kd (μM)
AdoMet – 3.3 ± 0.2
AdoHcy – 4.3 ± 0.7
SK&F 29661 AdoHcy 1.1 ± 0.2
SK&F 64139 – 0.88 ± 0.15
LY 134046 – 5.5 ± 0.4
a
Fluorescence data (λex 280 nm; λem 348 nm) were collected at room temperature. Dissociation constants were obtained by fitting data to eq 5.
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Table 5
Data from pH-rate profiles
pKa1 pKa2 pK a3
LogVa 6.63 ± 0.28 8.23 ± 0.36 8.93 ± 0.32
LogV/KPEAb – 8.66 ± 0.03 9.26 ± 0.03
LogV/KAdoMetb – 7.25 ± 0. 12 9.15 ± 0.12
pKi SK&F 29661b – 8.48 ± 0.04 9.08 ± 0.04
apKa values obtained by fitting to eq 7.
bpKa values obtained by fitting to eq 6.
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